Unique Technology
Based on fully human synthetic phage display librairies
Best in class scientific expertise
International research team with over 100 years of combined expertise
Proprietary antibody
Outstanding human antibodies assets available for partnering and licensing
TECHNOLOGY
- Proprietary synthetic Ab library
- In vitro screening methods validated on:
- - Integral membrane proteins
- - Soluble proteins
- - Peptides
PIPELINE
- Innovative therapeutics antibodies with unique pH sensitive properties for oncology
- Full adaptability to various pharmaceutical development formats: ADC, TCE, CAR-T…
ABOUT US
Mabqi, founded upon best
in class technology from Inserm,
is a biotech company with an integrated
approach to develop human antibodies.
LATEST NEWS
Mabqi is proud to co-author the scientific article « Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings» published in mAbs, November 2024.
05/12/2024
Karine Ponde de Leon2024-12-06T11:00:11+01:00The research project led by IOME Bio focused on developing antibodies targeting Repulsive Guidance Molecule b (RGMb), a novel...
Mabqi will be attending BIO EUROPE 2024
18/10/2024
Karine Ponde de Leon2024-10-18T10:07:06+02:00Mabqi will be attending the Festival of Biologics from October 15th to October 17th 2024 in Basel, Switzerland.
Mabqi will be attending the FOB 2024
01/10/2024
Karine Ponde de Leon2024-10-01T15:12:25+02:00Mabqi will be attending the Festival of Biologics from October 15th to October 17th 2024 in Basel, Switzerland.